bioRxivBioinformaticsPreprint
OBE-DB: A Computational Tool and Web Server for the Prediction of Antiobesity Drugs
Elena Murcia GarcíaiD, Carlos Martínez-CortésiD, Antonio Jesús Banegas‐LunaiD, Juan José Hernández MoranteiD, Horacio Pérez‐SáncheziD
Abstract
The huge obesity prevalence and its associated metabolic disorders highlight the urgent need for new therapeutic strategies beyond lifestyle interventions. Despite the availability of novel pharmacological treatments, the search for more effective and safe anti-obesity compounds remains a challenge. Recent advances in high-performance computational drug discovery have enabled the rapid screening and identification of potential anti-obesity compounds. However, these in silico procedures frequently require complex computational knowledge that limits the use of these techniques for most researchers. To address this gap, we have developed OBE-DB, an accessible and user-friendly platform integrating these computational tools that facilitates the prediction of potential anti-obesity molecules through two complementary approaches: (a) shape similarity analysis against a curated database of approved anti-obesity drugs, and (b) inverse virtual screening of user-submitted molecules against a set of therapeutic protein targets linked to obesity. Our results demonstrate that the server effectively screens and ranks compounds with high predicted activity, outperforming conventional in silico techniques in terms of accuracy and usability. This represents a significant advancement by providing researchers with an intuitive tool to accelerate early-stage drug discovery for obesity treatment. The server is freely accessible without registration, providing users with a detailed report via email upon completion of the predictions. This innovative database and web server is accessible online via http://bio-hpc.eu/software/obe-db/.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Computational evidence of a compound with nicotinic α4β2-Ach receptor partial agonist properties as possible coadjuvant for the treatment of obesity
Helena den-Haan, Juan José Hernández Morante, Horacio Pérez‐Sánchez·bioRxiv·Nov 16, 2016
- The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21
Suowen Xu, Zhenghong Liu, … Jianping Weng·Science AdvancesPeer-reviewed·Mar 26, 2025
- An Injectable Antisense Oligonucleotide (ASO) Approach to Treat Obesity in Preclinical Models
Simon T. Bond, Michael F. Keating, … Brian G. Drew·bioRxiv·Oct 19, 2026
- Enabling the hypothesis-driven prioritization of ligand candidates in big databases: Screenlamp and its application to GPCR inhibitor discovery for invasive species control
Sebastian Raschka, Anne M. Scott, … Leslie A. Kuhn·Journal of Computer-Aided Molecular DesignPeer-reviewed·Jan 29, 2018
- Computational Insight into Anti-Obesity Effects of Combined Some Phytobiotics to GLP1R (Glucagon-Like Peptide 1 Receptor) Protein in Anas javanica
Cindy Audina Damayanti, MAY Harahap, … Irfan Hadji Djunaidi·bioRxiv·Apr 26, 2023
- Computationally Guided Design of Dipeptidyl Peptidase-4 Inhibitors
L. C. Reynolds, M. P. Connolly, J. B. Siegel·bioRxiv·Sep 18, 2019